Literature DB >> 24754901

Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.

Frida Pauly1, Karin E Smedby2, Mats Jerkeman3, Henrik Hjalgrim4, Mattias Ohlsson5, Richard Rosenquist6, Carl A K Borrebaeck1, Christer Wingren7.   

Abstract

B-cell lymphoma (BCL) heterogeneity represents a key issue, often making the classification and clinical management of these patients challenging. In this pilot study, we outlined the first resolved view of BCL disease heterogeneity on the protein level by deciphering disease-associated plasma biomarkers, specific for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, using recombinant antibody microarrays targeting mainly immunoregulatory proteins. The results showed the BCLs to be heterogeneous, and revealed potential novel subgroups of each BCL. In the case of diffuse large B-cell lymphoma, we also indicated a link between the novel subgroups and survival.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  B-cell lymphoma; Biomarker; CLL; DLBCL; Disease heterogeneity; FL; MCL; Plasma protein profiling

Mesh：

Substances：

Year:  2014        PMID： 24754901     DOI： 10.1016/j.leukres.2014.03.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  7 in total

1.  Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.

Authors:  Anna Sandström Gerdtsson; Christer Wingren; Helena Persson; Payam Delfani; Malin Nordström; He Ren; Xin Wen; Ulrika Ringdahl; Carl A K Borrebaeck; Jihui Hao
Journal:  Mol Oncol       Date:  2016-07-12       Impact factor: 6.603

2.  Identification of a serum biomarker signature associated with metastatic prostate cancer.

Authors:  Venera Kuci Emruli; Leena Liljedahl; Ulrika Axelsson; Corinna Richter; Lisa Theorin; Anders Bjartell; Hans Lilja; Jenny Donovan; David Neal; Freddie C Hamdy; Carl A K Borrebaeck
Journal:  Proteomics Clin Appl       Date:  2021-05-04       Impact factor: 3.603

3.  Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

Authors:  F Pauly; K Fjordén; S Leppä; H Holte; M Björkholm; Ø Fluge; L Møller Pedersen; M Eriksson; A Isinger-Ekstrand; C A K Borrebaeck; M Jerkeman; C Wingren
Journal:  Blood Cancer J       Date:  2016-11-18       Impact factor: 11.037

4.  PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.

Authors:  Renato Franco; Giosuè Scognamiglio; Elena Valentino; Michela Vitiello; Antonio Luciano; Giuseppe Palma; Claudio Arra; Elvira La Mantia; Luigi Panico; Valentina Tenneriello; Antonello Pinto; Ferdinando Frigeri; Gaetana Capobianco; Gerardo Botti; Laura Cerchia; Annarosaria De Chiara; Monica Fedele
Journal:  Oncotarget       Date:  2016-09-13

Review 5.  Current applications of antibody microarrays.

Authors:  Ziqing Chen; Tea Dodig-Crnković; Jochen M Schwenk; Sheng-Ce Tao
Journal:  Clin Proteomics       Date:  2018-02-28       Impact factor: 3.988

Review 6.  Immunocapture strategies in translational proteomics.

Authors:  Claudia Fredolini; Sanna Byström; Elisa Pin; Fredrik Edfors; Davide Tamburro; Maria Jesus Iglesias; Anna Häggmark; Mun-Gwan Hong; Mathias Uhlen; Peter Nilsson; Jochen M Schwenk
Journal:  Expert Rev Proteomics       Date:  2015-11-11       Impact factor: 3.940

7.  Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.

Authors:  Laura Jacobs; Stefan Habringer; Jolanta Slawska; Katharina Huber; Elke Hauf; Zhoulei Li; Yosef Refaeli; Markus Schwaiger; Martina Rudelius; Axel Walch; Ulrich Keller
Journal:  Oncotarget       Date:  2017-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.